PA
PRAX icon

Parallel Advisors’s Praxis Precision Medicines PRAX Stock Holding History

Parallel Advisors’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-124
Closed -$40K – 4046
2026
Q1 		$40K Buy
124
+120
+3,000% +$37.1K ﹤0.01% 2122
2025
Q4 		$1.18K Buy
+4
New +$745 ﹤0.01% 3257
2025
Q1 		– Sell
-2
Closed -$154 – 3631
2024
Q4 		$154 Buy
+2
New +$145 ﹤0.01% 3409
2022
Q4 		– Sell
-25
Closed -$1K – 3491
2022
Q3 		$1K Buy
+25
New +$1.25K ﹤0.01% 2994
2022
Q1 		– Sell
-5
Closed -$1K – 3209
2021
Q4 		$1K Sell
5
-6
-55% -$1.76K ﹤0.01% 2937
2021
Q3 		$3K Buy
11
+8
+267% +$2.17K ﹤0.01% 2585
2021
Q2 		$1K Buy
+3
New +$1.07K ﹤0.01% 2801

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Parallel Advisors's PRAX Position: Q2 2026 in Review

Parallel Advisors sold out of Praxis Precision Medicines (PRAX) in Q2 2026, closing a stake of 124 shares — an estimated $40K sold.

Parallel Advisors first reported a position in PRAX in Q2 2021 and held it in 7 quarters. The position peaked at $40K in Q1 2026. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Parallel Advisors reported no remaining Praxis Precision Medicines position as of Q2 2026 after selling out during the quarter.
  • Parallel Advisors sold 124 Praxis Precision Medicines shares in Q2 2026, an estimated $40K.
  • Parallel Advisors first reported a position in Praxis Precision Medicines in Q2 2021 and held it in 7 quarters.
  • Parallel Advisors's Praxis Precision Medicines position peaked at $40K in Q1 2026.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.